Company / Cash & Equivalents
GERON CORP Cash & Equivalents History
FY2015-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cash & Equivalents
$79.0M
FY2024
5-year range
$9.9M / $79.0M
FY2020-FY2024
Trend
+12.8%
vs FY2023
Sector context
#161 of 207
Health Care
What the data says
GERON CORP's cash & equivalents of $79M is lower than 78% of companies in the Health Care sector (FY2024). Cash & Equivalents has increased for 4 consecutive years, from $10M in FY2020 to $79M in FY2024.
Based on SEC 10-K filings.
$79M in FY2024 with a 5-year CAGR of +42.1%.
Improved from $57M to $79M over the past 2 years.
Health Care sector context is included.
Cash & Equivalents over time
Growth rates
- 3-Year CAGR
- +31.3%
- 5-Year CAGR
- +42.1%
- 10-Year CAGR
- -
Sector benchmark
Bottom 22% in Health CareTop 78% of 207This company $79.0M Sector average $669.5M
▼
-88.2% below sector average
Key checks
Key Insights
- GERON CORP's cash & equivalents has grown for 4 consecutive years.
- 5-year CAGR of +42.1%, indicating consistent growth.
- In FY2024, cash & equivalents increased 12.8% year-over-year.
- Ranks #161 out of 207 companies in the Health Care sector.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.05 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cash & EquivalentsValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $79.0M | +12.8% |
| FY2023 | $70.0M | +23.2% |
| FY2022 | $56.8M | +63.0% |
| FY2021 | $34.9M | +251.3% |
| FY2020 | $9.9M | -27.3% |
| FY2019 | $13.6M | +29.0% |
| FY2018 | $10.6M | -35.3% |
| FY2017 | $16.3M | -61.8% |
| FY2016 | $42.8M | +229.5% |
| FY2015 | $13.0M | -41.1% |
As of FY2024 · SEC 10-K · Updated Jun 30, 2026